SCHEMBL5745167

SCHEMBL5745167

CCOc1cccc(C(=O)c2ncc(C=O)c3cc(OCCO)c(OC)cc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFPT1 Q06210 1/20 0.46
AURKB Q96GD4 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
ERN1 O75460 3/20 0.39
ZAP70 P43403 1/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KAT6A Q92794 1/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5743055 0.95 GFPT1 (0.45) GFPT1AURKBIRAK4RAF1BRAF
SCHEMBL5746837 0.92 GFPT1 (0.45) GFPT1RAF1BRAFERN1ZAP70
SCHEMBL5744649 0.92 GFPT1 (0.45) GFPT1RAF1BRAFERN1ZAP70
SCHEMBL5745700 0.91 GFPT1 (0.44) GFPT1RAF1BRAFERN1ZAP70
SCHEMBL5745348 0.89 GFPT1 (0.43) GFPT1RAF1BRAFERN1ZAP70
SCHEMBL5745709 0.88 GFPT1 (0.45) GFPT1RAF1BRAFERN1ZAP70
SCHEMBL5746027 0.87 GFPT1 (0.56) GFPT1RAF1BRAFZAP70KMT2A
SCHEMBL5744828 0.87 GAA (0.47) GFPT1ZAP70KDM4EMAPTPDE10A
SCHEMBL5766291 0.86 HRH3 (0.45) KMT2AKDM4EALDH1A1
SCHEMBL5744647 0.86 GFPT1 (0.44) GFPT1AURKBIRAK4RAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067529-B2 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors HOFFMANN-LA ROCHE INC. (US) 2006-06-27 US disclosed
EP-1631551-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-08 EP disclosed
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors BOLIN DAVID ROBERT (US) 2004-12-23 US disclosed
WO-2004101528-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors GFPT1, GLS2, GLS GFPT1 1/4885AURKB 4086/4885IRAK4 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.